LGALS3
Galectin-3
As of the edition of 20 October 2026, LGALS3 (galectin-3, UniProt P17931) has 6 drugs tested at it and 4 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P17931
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 183
- Disease areas
- Cancer; Digestive system; Lungs and airways; Skin and connective tissue; Mental health; Nervous system; Heart and blood vessels; Infections
- Registered trials of its drugs
- 25
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Stopped | 3 |
| Status not established | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| TB006 | Active | Phase 2 | none listed |
| Selvigaltin | Stopped | Phase 2 | none listed |
| Belapectin | Stopped | Phase 3 | none listed |
| Davanat | Stopped | Phase 2 | none listed |
| Olitigaltin | Status not established | Phase 2 | none listed |
| HT-2157 | Went quiet | Phase 2 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Galectin Therapeutics | Route A |
| Dart NeuroScience | Route A |
The other 2 companies at LGALS3
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at LGALS3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.